Trials / Available
AvailableNCT07332338
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- StemCyte, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.
Detailed description
A total of 30 subjects with post-COVID will be enrolled.
Conditions
- Post-COVID-19 Condition
- Post-COVID Condition
- Post-COVID Syndrome
- Long COVID
- Chronic Fatigue
- Chronic Fatigue Symptoms
- Fatigue Post Viral
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | REGENECYTE® | HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood) |
Timeline
- First posted
- 2026-01-12
- Last updated
- 2026-03-23
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT07332338. Inclusion in this directory is not an endorsement.